Xgeva

Anemic Growth? Not From These Drugs.

Anemic Growth? Not From These Drugs.

Motley Fool

FDA rejects Amgen's application for Xgeva

FDA rejects Amgen's application for Xgeva

Reuters

A Picture is Worth a Thousand Words: The Difference Between "Yes" and "No" During an FDA Advisory Committee

A Picture is Worth a Thousand Words: The Difference Between "Yes" and "No" During an FDA Advisory Committee

Elsevier Business

FDA panel votes against Xgeva for prostate cancer

FDA panel votes against Xgeva for prostate cancer

Yahoo/AP

Can Amgen Convince Docs to Recommend Xgeva Approval?

Can Amgen Convince Docs to Recommend Xgeva Approval?

Motley Fool

FDA questions benefit of Amgen's bone drug for new use in prostate cancer patients

FDA questions benefit of Amgen's bone drug for new use in prostate cancer patients

Yahoo/AP

Amgen risk/reward attractive into Xgeva panel, says Deutsche Bank

Amgen risk/reward attractive into Xgeva panel, says Deutsche Bank

Yahoo/Fly on the Wall

FDA Pharma Meetings for February

FDA Pharma Meetings for February

Motley Fool

Amgen: Xgeva panel review scheduled for February

Amgen: Xgeva panel review scheduled for February

Yahoo/AP